Formosa Pharmaceuticals, Inc. (TPE:6838)

Formosa Pharmaceuticals Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	291.83	425.79	384.71	267.34	208.92	41.87
Short-Term Investments	1,220	1,220	831.41	153.55	-	-
Cash & Short-Term Investments	1,512	1,646	1,216	420.89	208.92	41.87
Cash Growth	-9.18%	35.33%	188.94%	101.46%	398.99%	-49.77%
Other Receivables	20.98	51.66	46.44	14.72	13.88	10.21
Receivables	21.89	51.66	46.44	14.72	13.88	10.21
Inventory	4.45	2.89	-	-	-	-
Prepaid Expenses	6.4	26.94	25.34	20.57	11.66	0.69
Other Current Assets	0.77	0.52	0.44	0.13	0.04	1.76
Total Current Assets	1,545	1,728	1,288	456.31	234.5	54.52
Property, Plant & Equipment	41.7	29.89	34.36	10.18	8.19	14.11
Long-Term Investments	4.29	5.15	27.26	-	-	-
Goodwill	30.54	30.54	30.54	30.54	30.54	30.54
Other Intangible Assets	442.25	311.85	345.64	380.2	414.83	362.02
Other Long-Term Assets	42.02	7.05	0.65	0.67	0.65	0.65
Total Assets	2,106	2,112	1,727	877.91	688.72	461.85
Accrued Expenses	93.81	128.36	86.67	66.09	7.17	3.2
Current Portion of Leases	5.04	5.5	5.5	2.5	2.76	3.03
Current Unearned Revenue	25.5	4.51	71.33	-	-	-
Other Current Liabilities	35.59	59.59	94.48	0.98	9.37	39.64
Total Current Liabilities	161.4	197.95	257.98	69.57	19.3	45.88
Long-Term Leases	19.7	20.3	24.29	4.41	0.42	3.18
Long-Term Unearned Revenue	16.76	23.48	1.66	-	-	-
Long-Term Deferred Tax Liabilities	3.58	3.95	4.45	4.94	5.43	5.93
Other Long-Term Liabilities	394.26	318.02	297.84	331.6	270.33	206.95
Total Liabilities	595.7	563.7	586.21	410.51	295.48	261.93
Common Stock	1,510	1,510	1,341	1,136	988.32	728.32
Additional Paid-In Capital	2,279	2,279	1,780	978.52	620.49	270.49
Retained Earnings	-2,189	-2,153	-1,952	-1,630	-1,202	-800.65
Comprehensive Income & Other	-90.31	-87.59	-29.91	-18.14	-14.53	1.23
Total Common Equity	1,510	1,548	1,140	466.83	392.74	199.38
Minority Interest	0.53	0.59	0.54	0.57	0.49	0.53
Shareholders' Equity	1,510	1,549	1,141	467.4	393.23	199.92
Total Liabilities & Equity	2,106	2,112	1,727	877.91	688.72	461.85
Total Debt	24.73	25.8	29.79	6.9	3.18	6.21
Net Cash (Debt)	1,487	1,620	1,186	413.99	205.74	35.66
Net Cash Growth	-9.17%	36.55%	186.56%	101.22%	476.99%	-53.79%
Net Cash Per Share	10.00	11.50	9.56	3.94	2.22	0.51
Filing Date Shares Outstanding	150.98	150.98	134.14	113.64	98.83	98.83
Total Common Shares Outstanding	150.98	150.98	134.14	113.64	98.83	98.83
Working Capital	1,384	1,530	1,030	386.75	215.2	8.64
Book Value Per Share	10.00	10.25	8.50	4.11	3.97	2.02
Tangible Book Value	1,037	1,206	763.85	56.09	-52.64	-193.18
Tangible Book Value Per Share	6.87	7.99	5.69	0.49	-0.53	-1.95
Machinery	23.16	8.14	7.38	7.44	7.44	50.45
Construction In Progress	-	-	-	-	-	0.36
Leasehold Improvements	0.7	0.7	0.45	1.54	1.54	1.32

Source: S&P Global Market Intelligence. Standard template. Financial Sources.